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http://dx.doi.org/10Mammalian erythroblasts undergo enucleation through a process thought to be similar to
cytokinesis. Microtubule-organizing centers (MTOCs) mediate organization of the mitotic
spindle apparatus that separates the chromosomes during mitosis and are known to be crucial
for proper cytokinesis. However, the role of MTOCs in erythroblast enucleation remains un-
known. We therefore investigated the effect of various MTOC inhibitors on cytokinesis and
enucleation using human colony-forming units–erythroid (CFU-Es) and mature erythroblasts
generated from purified CD34+ cells. We found that erythro-9-[3-(2-hydroxynonyl)]adenine
(EHNA), a dynein inhibitor, and monastrol, a kinesin Eg5 inhibitor, as well as various inhib-
itors of MTOC regulators, including ON-01910 (Plk-1), MLN8237 (aurora A), hesperadin
(aurora B), and LY294002 (PI3K), all inhibited CFU-E cytokinesis. Among these inhibitors,
however, only EHNA blocked enucleation. Moreover, terminally differentiated erythroblasts
expressed only dynein; little or none of the other tested proteins was detected. Over the course
of the terminal differentiation of human erythroblasts, the fraction of cells with nuclei at the
cell center declined, whereas the fraction of polarized cells, with nuclei shifted to a position
near the plasma membrane, increased. Dynein inhibition impaired nuclear polarization,
thereby blocking enucleation. These data indicate that dynein plays an essential role not
only in cytokinesis but also in enucleation. We therefore conclude that human erythroblast
enucleation is a process largely independent of MTOCs, but dependent on dynein. Copy-
right  2016 ISEH - International Society for Experimental Hematology. Published by Elsev-
ier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Mammalian erythropoiesis culminates in enucleation, an
incompletely understood process entailing the expulsion
of the nucleus from the cytoplasm of erythroblasts. During
erythropoiesis, stem cells undergo lineage-specific commit-
ment and generate erythroid progenitor cells through
cellular division events that include both nuclear (mitosis)
and cytoplasmic (cytokinesis) division. These progenitor
cells consist of burst-forming units–erythroid (BFU-Es)
and their progeny, colony-forming units–erythroid (CFU-: Wataru Nunomura, Department of Life Science,
ngineering and Resource Science, Akita University,
Akita 010-8502, Japan; E-mail: nunomura@gipc.
related to this article can be found online at http://
exphem.2015.12.003.
 2016 ISEH - International Society for Experimental Hem
se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2015.12.003Es) [1–4]. Then over an additional 6 to 7 days, the CFU-
Es proliferate and differentiate into mature erythroblasts
[1,5]. During terminal differentiation, mammalian erythro-
blasts undergo enucleation, becoming reticulocytes and,
subsequently, mature erythrocytes. The expelled nuclei
are phagocytosed by reticular cells such as macrophages
(for a review, see [6]).
The process of enucleation is thought to be similar to
cytokinesis, and many of the general principles of cytoki-
nesis apply to enucleation. In both cytokinesis and enucle-
ation, the cytoskeleton is key in the choice and positioning
of the division site. Once this site is chosen, there is local
assembly of a contractile actomyosin ring, during which
nonmuscle myosin IIB remodels the plasma membrane
[5]. Trafficking of the necessary components to the division
site and membrane fusion lead to the physical separation of
the daughter cells (for a review, see [7,8]). Wang et al.atology. Published by Elsevier Inc. This is an open access article under the
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sitide 3-kinase (PI3K) is important for the enucleation [9].
During polarization, the nucleus becomes displaced to one
side of the cell, near the plasma membrane, while actin be-
comes restricted to the other side, where dynamic cyto-
plasmic contractions generate pressure that pushes the
viscoelastic nucleus through a narrow constriction in the
cell surface, forming a bud. These findings implicate
PI3K and its products in the polarization and enucleation
of erythroblasts [9].
Microtubule-organizing centers (MTOCs) function as
sites where microtubule formation begins, as well as loca-
tions where free ends of microtubules are attracted to pro-
teins anchored in the cytoplasmic membrane [10]. The most
notable MTOCs are the centrosomes formed during inter-
phase and the mitotic spindle poles. Thus, MTOCs are
essential for proper cytokinesis. The degree to which
MTOCs contribute to the enucleation of terminally
differentiated erythroblasts remains unknown, however.
g-Tubulin is a member of the tubulin family and is impor-
tant for nucleation and polar orientation of microtubules
[10,11]. g-Tubulin is an abundant component of centro-
somes and spindle pole bodies, where it is found within
g-tubulin ring complexes, which chemically mimic the
plus end of microtubules, thus enabling microtubules to
bind [12,13]. Another molecule, the motor protein dynein,
mediates unidirectional movement toward MTOCs (minus
end of microtubules), whereas kinesins ‘‘walk’’ along
microtubule filaments toward the plus end, often enabling
transport of cargo from the cell center toward the periphery
[14–16]. The motor functions of both dynein and kinesins
are known to support cytokinesis, but their roles in erythro-
blast enucleation remain unclear [17–19].
In the present study, therefore, we investigated the con-
tributions made by dynein, kinesin, Eg5, and several
MTOC regulatory proteins to the process of human eryth-
roblast enucleation. Here we illustrate that although the
motor proteins dynein and Eg5 and the various MTOC reg-
ulatory proteins tested were all needed for CFU-E cytoki-
nesis (proliferation), only dynein was necessary for the
cell division and nuclear polarization during terminal
erythroblast differentiation and enucleation. Enucleation
is thus independent of most MTOC-related proteins, but
dependent on dynein.Methods
Cell preparations
Granulocyte colony-stimulating factor (G-CSF)-mobilized human
peripheral blood CD34þ cells were purified from healthy volun-
teers as described previously and stored in liquid nitrogen until
required. Informed consent was obtained from all subjects prior
to their entry into this study, and the study was pre-approved by
the Akita University Graduate School of Medicine Committee
for the Protection of Human Subjects [2].To generate erythroid progenitor cells, CD34þ cells were
thawed and prepared for culture as previously described [2]. Cells
were cultured in Iscove’s modified Eagle’s medium (IMDM),
erythroid medium containing 20% fetal calf serum (FCS), 10%
heat-inactivated pooled human AB serum, 1% bovine serum albu-
min (BSA), 10 mg/mL insulin, 0.5 mg/mL vitamin B12, 15 mg/mL
folic acid, 50 nmol/L b-mercaptoethanol (b-ME), 50 U/mL peni-
cillin, and 50 mg/mL streptomycin in the presence of 50 ng/mL
interleukin (IL)-3, 50 ng/mL stem cell factor (SCF), and 2 IU/
mL erythropoietin (EPO). Cells were maintained at 37C in a
5% CO2 incubator. On day 7 of culture (D7), the cells were har-
vested and washed three times with IMDM containing 0.1%
BSA and stored at 4C until required. The maturation level of
the D7 cells was similar to that of CFU-Es, as reported elsewhere
[2,3]. Hereafter, D7 cells will be referred to as CFU-Es. Because
the cells were not completely synchronized, the effects of inhibi-
tors on cell proliferation and the enucleation ratio (describe in the
Supplementary Methods, online only, available at www.exphem.
org) were decided after incubation for 24 h.
Aliquots of CFU-Es were then cultured in erythroid medium
with EPO alone, without b-mercaptoethanol, SCF, or IL-3 to induce
differentiation with or without various the inhibitors of cell division.
The volume of inhibitor and control solutions (H2O or dimethyl
sulfoxide [DMSO]) was fixed at 5% of the erythroid medium.
The final concentration of DMSO in the erythroid medium was
0.1% (v/v), as higher concentrations are toxic to human erythroid
progenitors. The cells were harvested at various times, washed three
times with IMDM containing 0.1% BSA, resuspended in IMDM
containing 0.1% BSA, and stored at 4C until required.
Morphologic and immunochemical analysis of cells cultured
with and without inhibitors
The cells were classified based on the whether the nucleus was
localized at the center of the cells (centered); the cells were spher-
ical containing a condensed nucleus located to one side, close to
the plasma membrane (polarized); or the cells were enucleated
(reticulocytes). Other cell types, such as multinucleate cells and
cells with condensed apoptotic nuclei, were classified as ‘‘other.’’
Images of cells classified as described are provided in
Supplementary Figure E1 (online only, available at www.
exphem.org). The fractions of each cell type were calculated as
described in the previous section. Results are presented as the
means 6 SD of three independent experiments.
Immunochemical distributions of g-tubulin and dynein were
determined using confocal microscopy as described above. D10
cells were cultured in the presence or absence of 400 mmol/L er-
ythro-9-[3-(2-hydroxynonyl)]adenine (EHNA).
Other information
Additional methods and details of are described in the
Supplementary Methods.Results
Dynein inhibitor blocks division of CFU-Es
We first examined the effects of inhibitors of cell division
on primary human CFU-Es generated from purified
CD34þ cells. Given that cellular division consists of both
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should block cell proliferation, effective inhibitors were
defined as those that blocked CFU-E proliferation.
Figure 1A and B illustrates total cell numbers and
morphology when human CFU-Es were cultured without
inhibitors. EHNA, a specific inhibitor of dynein ATPase ac-
tivity, completely blocked cell proliferation (Fig. 1C).
Among the cells incubated with a motor protein inhibitor,
the fraction of cells in G1/G0/S phase (46.0 6 0.6% for
EHNA, as illustrated in Fig. 1D) was little changed from
control, though there was a significant reduction in the
mitotic fraction (4n!). The morphology of the EHNA-
treated cells was similar to that of control cells at 0 hours
(Fig. 1E). No multinucleate cells were observed among
the cells incubated with 400 mmol/L EHNA. To avoid the
possibility of a nonspecific effect of EHNA on the prolifer-
ation of CFU-Es, dynein and a-tubulin expression was
analyzed using Western blotting (Supplementary
Figure E2, all supplementary figures are online only, avail-
able at www.exphem.org), whereas expression of CD71 and
glycophorin A (GPA) was analyzed using fluorescence-
activated cell sorting (FACS) (Supplementary Figure E3).
There was no nonspecific effect on the expression of dynein
or a-tubulin. The levels of CD71 and GPA expression indi-
cated that EHNA inhibited cell proliferation. We also exam-
ined the effect of EHNA on gene expression of GATA1 and
GLUT1 (Supplementary Figure E4), but found no signifi-
cant changes in cells cultured with or without EHNA for
24 h. Mitotic kinesin Eg5, serving as a control motor pro-Figure 1. Dynein inhibitor blocks CFU-E proliferation. Human D7 CFU-Es gener
presence of EPO with or without the dynein inhibitor EHNA. (A) Cell cycle analys
cells after culture for 0, 24, or 48 hours without inhibitors. (C) Effects of the indicat
presented as the means 6 SD of three independent experiments. (D) Cell cycle ana
lines) 400 mmol/L EHNA. A representative result from three independent experime
D8–D9 cells after culture for 24 or 48 hours with or without 400 mmol/L EHNA. A
no multinucleate cells were found among those incubated with 400 mmol/L EHNA.tein moving in the opposite direction of dynein, was blocked
by monastrol, which was previously reported to affect cell
proliferation [5,20,21]. Our present findings confirm those
earlier results (Supplementary Figure E5A–C). Or results
also indicate that EHNA selectively inhibits dynein with
no nonspecific effects. No multinucleate cells were
observed after treatment with high concentrations of
EHNA, which indicates that EHNA does not affect actin
polymerization. Thus, EHNA specifically blocks human
CFU-E proliferation as effectively as monastrol [5].
Inhibition of MTOC regulators blocks CFU-E
proliferation
ON-01910, an inhibitor of Plk1, which is an early trigger
for G2/M transition; MLN8237, an inhibitor of aurora A,
which is associated with centrosome maturation and separa-
tion and, thus, regulates spindle assembly and stability; and
hesperadin, an inhibitor of aurora B, which functions in the
attachment of the mitotic spindle to the centromere all
completely blocked CFU-E proliferation (Fig. 2A). Cell cy-
cle analysis revealed that ON-01910 reduced the cell frac-
tion in G1/G0 phase, leading to accumulation of cells in S
(13.7 6 1.9%) and G2/M (24.7 6 1.9%) phases, and
dramatically increased the dead cell fraction
(32.8 6 3.2%) (Fig. 2B). Many CFU-Es treated with ON-
01910 for 48 hours exhibited nuclear fragmentation charac-
teristic of early apoptosis (Fig. 2C). Treatment with
MLN8237 also significantly reduced the cell fraction in
G1/G0 phase (35.4 6 1.3%), resulting in the accumulationated from purified CD34þ cells were cultured for the indicated periods in the
is of D7 cells without inhibitors. (B) May–Gr€unwald–Giemsa staining of D7
ed concentrations of inhibitors or vehicle on CFU-E proliferation. Results are
lysis of D8 cells after culture for 24 hours with (red areas) or without (solid
nts is presented as the mean 6 SD. (E) May–Gr€unwald–Giemsa staining of
representative result from three independent experiments is shown. Note that
The results indicated that EHNA did not have effects on actin. Bar 5 10 mm.
Figure 2. Inhibition of MTOC regulators blocks CFU-E proliferation. Human D7 CFU-Es were cultured for the indicated periods in the presence of EPO
with or without inhibitors of Plk1 (ON-01910), aurora A (MLN8237) and aurora B (hesperadin). (A) Effects of the indicated concentrations of inhibitor or
vehicle on CFU-E proliferation. Results presented are the means 6 SD of three independent experiments. (B) Cell cycle analysis of D8 cells after culture for
24 hours with (red areas) 1,000 nmol/L ON-01910, 1,000 nmol/L MLN8237, or 100 nmol/L hesperadin. A representative result from among three indepen-
dent experiments is presented as the mean 6 SD. (C) May–Gr€unwald–Giemsa staining of D8–D9 cells after culture for 24 or 48 hours with or without
1,000 nmol/L ON-01910, 1,000 nmol/L MLN8237, or 100 nmol/L hesperadin. A representative result from three independent experiments is shown.
Bar 5 10 mm.
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(Fig. 2B). Hesperadin treatment led to an even greater
reduction in G1/G0 cells (27.2 6 4.5%) and a correspond-
ing increase in G2/M cells (20.0 6 2.9%). Abnormally
shaped nuclei and multinuclear cells also appeared among
hesperadin-treated CFU-Es (Fig. 2C). Consistent with
earlier reports, we found that the phosphoinositide 3-
kinase (PI3K) inhibitor LY294002 blocks CFU-E prolifera-
tion with an increase in the dead cell fraction (10.86 1.9%)
as compared with control (5.9 6 1.2%) (Supplementary
Figure E5D and E) [9,22]. LY294002 also induced signifi-
cant morphologic changes, as illustrated in Supplementary
Figure E5F. These results indicate that blocking MTOCs
completely inhibits the proliferative capacity of human
erythroid progenitor cells.
Inhibition of dynein blocks erythroblast enucleation, but
not MTOC inhibitors
Time-dependent changes in the enucleation fraction when
human D10 erythroblasts were cultured for 72 hours with
(Figure 3D showing cell cycles and Fig. 3C, closed circles)
or without (Figure 3A showing cell cycles and Fig. 3C,
open circles) various concentrations of the dynein inhibitorEHNA are provided. Mature untreated erythroblasts differ-
entiated and began the enucleation process (Fig. 3B).
EHNA dose-dependently inhibited the increase in the
enucleation fraction, and the nucleus remained in the center
of cells (Fig. 3E). The absence of a nonspecific effect of
EHNA (400 mmol/L) on enucleation was confirmed by
the expression of dynein and a-tubulin (Supplementary
Figure E6), as well as CD71 and GPA (Supplementary
Figure E7). There were no significant differences in the
gene expression of GATA1 and GLUT1 after culture of
cells for 48 hours with or without EHNA (Supplementary
Figure E8). As reported previously, monastrol did not block
human erythroblast enucleation (Supplementary
Figure E9A–C) [5]. Figure 4 illustrates that none of the
MTOC inhibitors tested in this study blocked enucleation.
Morphologic analysis of cells cultured with or without
inhibitors
We next assessed the effect of MTOC and motor protein in-
hibitors on the positioning of the nucleus during terminal
differentiation of human D10 erythroblasts (Table 1). The
cells were classified as described under Methods and in
Supplementary Figure E1. Among these cells, the centered
Figure 3. Inhibitors of dynein enucleation of erythroblasts. Human D7 CFU-Es were cultured with EPO for an additional 3 days (until D10). By then they
had differentiated to mature erythroblasts at a stage prior to enucleation. Culture was then continued in the presence of EPO with or without inhibitor of
dynein (EHNA). (A) Cell cycle analysis of D10 cells without inhibitors. (B) May–Gr€unwald–Giemsa staining of D10 cells after culture for 0, 24, 48, or
72 hours without inhibitors. (C) Effects of the indicated concentrations of inhibitor or vehicle on enucleation of D10–D13 erythroblasts. Results are presented
as means 6 SD of three independent experiments. (D) Cell cycle analysis of D10 cells after culture for 24 hours with (red areas) or without (black lines)
400 mmol/L EHNA. A representative result from three independent experiments is presented as the mean 6 SD. (E) May–Gr€unwald–Giemsa staining of
D11–D13 cells after culture for 24, 48, or 72 hours with or without 400 mmol/L EHNA. A representative result from three independent experiments is shown.
Bar 5 10 mm.
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68.5% to 76.1%) and 16.7 6 1.6% (range, 14.6% to
19.3%), respectively. After incubation of the cells for an
additional 24 hours with no inhibitors, the centered and
polarized fractions had changed to 46.9 6 4.4% (range,
43.9%–53.2%) and 21.5 6 3.1% (range, 15.7%–24.3%),
respectively. Over the same 24 h, the reticulocyte fraction
increased from 7.7 6 1.4% (range, 5.3%–9.0%) to
29.6 6 3.7% (range, 28.0%–30.5%).
Inhibiting dynein using EHNA significantly inhibited the
decline in the centered cell fraction and the increase in the
reticulocyte fraction that were seen in untreated control
cells over the 24-h period from D10 to D11 (Table 1 and
Supplementary Figure E10). By contrast, inhibition of kine-
sin Eg5 using monastrol had no effect on nuclear posi-
tioning, nor did inhibition of PI3K. Treatment with the
aforementioned inhibitors of Plk1, aurora A, or aurora B
led to reductions in the centered cell fraction (Table 1
and Supplementary Figure E10).
Expression of g-tubulin, motor proteins, and MTOC
regulators in human erythroblasts
Because the dynein inhibitor EHNA increased the centered
cell fraction in day 10–11 cells and blocked erythroblast
enucleation, we investigated the expression of MTOC-
related proteins during terminal differentiation of human
erythroblasts. g-Tubulin was immunochemically detected
in the cytoplasm in erythroblasts from D7 (CFU-E) to
D13 (late-stage erythroblasts and reticulocytes) (Fig. 5),
and the expression of g-tubulin did not to change duringthat period. Western blotting revealed that dynein was ex-
pressed during terminal erythroblast differentiation
(Fig. 5). Little or no Eg5, Plk1, aurora A or aurora B was
expressed in D13 (Fig. 5). These results suggest dynein is
a key regulator of nuclear positioning and enucleation in
terminally differentiated erythroblasts.
Distribution of dynein and g-tubulin in erythroblasts
during terminal differentiation
In D7 CFU-Es, g-tubulin was immunochemically detected
around the periphery of the nucleus and in the cleavage
furrow, and a-tubulin (microtubules) was localized around
the g-tubulin (Fig. 6A). In D11 cells, the nucleus was dis-
placed to one side of the cell, and g-tubulin was located in
the center of cell (Supplementary Figure E11). Although
dynein was broadly distributed in the cytoplasm and did
not co-localize with a-tubulin in D8 cells, in D11 cells, it
was distributed in aggregates on the periphery of the nu-
cleus and co-localized with a-tubulin at or near the MTOCs
(Fig. 6B and Supplementary Figure E12 containing high-
magnification images). Treating the D10 cells with
400 mmol/L EHNA blocked dynein aggregation such that
it remained diffuse in the cytoplasm (Fig. 6B). In contrast
to dynein, Eg5 co-localized with a-tubulin at the cleavage
furrow in mitotic CFU-Es (Supplementary Figure E13A).
In D7 and D8 CFU-Es, Plk1 and aurora B also co-
localized with a-tubulin at the cleavage furrow
(Supplementary Figure E13B and D), and aurora A local-
ized around the spindles in D7 cells (Supplementary
Figure E13C). But little if any Eg5, Plk1, aurora A, or
Figure 4. Inhibitors of MOTCs do not block erythroblast enucleation. D10 cells were cultured for 3 days in the presence of EPO with or without the in-
hibitors Plk1 (ON-01910), aurora A (MLN8237), and aurora B (hesperadin). (A) Effects of the indicated concentrations of inhibitors or vehicle on enucle-
ation of D11–D13 erythroblasts. Results are presented as the means6 SD of three independent experiments. (B) Cell cycle analysis of D11 cells after culture
for 24 hours with (red areas) or without (black lines) 1,000 nmol/L ON-01910, 1,000 nmol/L MLN8237, or 100 nmol/L hesperadin. A representative result
from three independent experiments is presented as the mean 6 SD. (C) May–Gr€unwald–Giemsa staining of D11–D13 cells after culture for 24, 48, or
72 hours with or without 1,000 nmol/L ON-01910, 1,000 nmol/L MLN8237, or 100 nmol/L hesperadin. A representative result from three independent ex-
periments is shown. Bar 5 10 mm.
252 I. Kobayashi et al./ Experimental Hematology 2016;44:247–256aurora B was detected in D11 cells (Supplementary
Figure E13A–D). Taken together, these results suggest
that accumulation of dynein around the MTOCs is neces-
sary for polarization and subsequent enucleation of
erythroblasts.Discussion
In the present study, we found that among the motor pro-
teins and MTOC regulatory proteins tested, only dynein
was necessary for cell division and nuclear polarization
during terminal differentiation and enucleation. Kinesin
Eg5 and the MTOC regulators Plk1, aurora A, and aurora
B were absent or dispensable. Our findings thus indicate
that enucleation is a process apparently independent of
MTOC-related proteins, but dependent on dynein.
During differentiation of CFU-Es into mature erythro-
blasts lacking the ability to divide, the cells repeatedly un-
dergo mitosis and cytokinesis. Furthermore, CFU-Es will
not differentiate into erythroblasts if mitosis or cytokinesis
is inhibited. On the other hand, enucleation of human eryth-
roblasts does not require mitosis. Because the relation be-
tween inhibition of cell division or maturation and
blocking of enucleation is conflated in some reports, we
suggest it is important for studies to clearly distinguisherythroblast enucleation from mitosis and cytokinesis.
Our present study satisfies that condition, as we compared
CFU-E mitosis and cytokinesis with nonproliferating
mature erythroblasts.
Thom et al. reported that Trim58 functions as an E3
ubiquitin ligase that facilitates protein degradation and is
expressed during terminal differentiation of human and
mouse erythroblasts [23]. Moreover, they suggest that
Trim58-mediated complete dynein degradation may be
responsible for nuclear movement during enucleation. We
also compared the expression of Trim58 and dynein immu-
nochemically using antibodies targeting dynein intermedi-
ate chain 1 or dynein light intermediate chain 2. Like
Thom et al, we found that Trim58 levels increased during
the period from D7 to D13. But in contrast to those inves-
tigators, we found that low levels of dynein persisted within
human erythroblasts throughout their terminal differentia-
tion (Supplementary Figure E14). Apparently, complete
degradation of dynein is not essential for cell polarization
prior to enucleation of human erythroblasts. Notably,
Thom et al. used mouse fetal liver erythroblasts, whereas
we used erythroblasts derived from human CD34þ cells pu-
rified from peripheral blood [23]. The discrepancy between
our results and those of Thom et al. may reflect this species
difference.
Table 1. Morphologic analysis of cells cultured with or without inhibitors*
Inhibitor Centered Polarized Other Reticulocytes
Control
0 h 76.1 6 3.3 16.0 6 2.9 1.2 6 0.2 6.7 6 0.7
24 h 48.1 6 6.3 22.9 6 3.7 1.0 6 0.6 28.0 6 5.5
EHNA 400 mmol/L 67.4 6 1.9y 21.0 6 2.1 0.4 6 0.5 11.1 6 0.7z
Control
0 h 75.3 6 1.7 16.9 6 2.6 2.3 6 1.0 5.5 6 1.8
24 h 43.9 6 5.2 23.4 6 2.1 2.3 6 1.9 30.5 6 8.0
Monastrol 100 mmol/L 47.1 6 3.7 21.1 6 2.1 5.3 6 3.1 26.6 6 5.0
Control
0 h 68.5 6 2.9 19.3 6 3.5 13.6 6 1.6 8.7 6 3.6
24 h 46.2 6 1.9 23.2 6 3.7 2.4 6 1.7 28.1 6 1.0
ON-01910 1,000 nmol/L 33.1 6 5.4x 15.3 6 2.7x 19.9 6 1.7y 31.7 6 5.5
Control
0 h 73.3 6 2.3 18.2 6 1.7 3.1 6 0.5 5.3 6 1.5
24 h 47.4 6 2.7 21.5 6 4.3 2.6 6 1.5 28.5 6 1.3
MLN8237 1,000 nmol/L 52.6 6 5.3 15.9 6 0.7 3.6 6 0.8 28.0 6 4.1
Hesperadin 100 nmol/L 33.6 6 2.5z 20.7 6 2.9 17.7 6 2.0y 28.1 6 3.6
Control
0 h 73.0 6 2.2 18.4 6 2.7 1.4 6 1.0 7.3 6 0.7
24 h 46.0 6 1.2 24.3 6 3.8 1.1 6 0.9 28.7 6 3.9
LY294002 100 mmol/L 48.4 6 6.3 26.0 6 3.1 0.6 6 0.2 25.1 6 3.7
EHNA 5 erythro-9-[3-(2-hydroxynonyl)]adenine.
*Centered refers to cells in which the nucleus was localized at the center of the cell. Polarized refers to spherical cells, which contained a condensed nucleus
located to one side, near the plasma membrane. Reticulocytes refer to enucleated c. Other cell types, such as multinucleate cells and cells with condensed
apoptotic nuclei, were classified as ‘‘other.’’ Images of cells classified as described are shown in Supplementary Figure E1 (online only, available at www.
exphem.org). The fractions of each cell type were calculated as described in the text. Results are presented as the mean 6 SD of three independent
experiments.
ySignificantly increased, p ! 0.01.
zSignificantly decreased, p ! 0.01.
xSignificantly decreased, p ! 0.05.
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tiation of erythroblasts from CFU-Es was 7 days in humans,
but only 2 days in mice. Although knockdown of dynein or
Trim58 in our system should be considered to explain this
discrepancy, we have not yet succeeded in transfecting the
siRNA and/or its expression vectors. Further experiments
are needed to clarify this discrepancy.Figure 5. Expression of dynein, Eg5, and MTOC regulators during human eryth
and D11), and enucleated cells (D13). Human CFU-Es were generated from pur
EPO. Protein collected from 1  105 D7–D13 cells was applied to each lane.
analyzed. The relative expression levels of the proteins were normalized to the
employed for the Western blot.Dynein mediates unidirectional nuclear movement toward
MTOCs, whereas kinesin Eg5 walks toward the plus end of
microtubules [14,16,24,25]. We observed that moving the nu-
cleus requires dynein, but not Eg5, and that dynein accumu-
lates at or near MTOCs in D11 cells (Fig. 6B). It is not yet
known precisely what dynein carries from the plasma mem-
brane to MTOCs in human erythroblasts. Keerthivasan et al.ropoiesis. Western blot analyses of human CFU-Es (D7), erythroblasts (D9
ified CD34þ cells and cultured for the indicated periods in the presence of
Expression of g-tubulin, dynein, Eg5, aurora A, aurora B, and Plk1 was
level of a-tubulin expression. Anti-dynein light intermediate chain 1 was
Figure 6. Distribution of tubulin and dynein in D11 cells with or without EHNA treatment. Confocal micrographs of CFU-Es (D7 or D8) and erythroblasts
(D11) stained with DAPI (blue) or antibodies against g-tubulin (A) or dynein (green, anti-dynein light intermediate chain 1 antibody was employed, (B) and
a-tubulin (red). Overlapping staining in the merged images is shown in yellow. Differential interference contrast microscopic image (DIC) is shown. W and
WO respectively denote D10 cells treated for 24 hours with and without 400 mmol/L EHNA. Bar 5 10 mm.
254 I. Kobayashi et al./ Experimental Hematology 2016;44:247–256reported that in mouse fetal liver erythroblasts, vesicles accu-
mulate at the site of nuclear extrusion and form a vacuole
essential for enucleation, and that enucleation is blocked by in-
hibitors for vesicle trafficking [26]. Those results illustrate that
the function of dynein in the enucleation of human erythro-
blasts is the trafficking of vesicles. It has also been suggested
that dynein may be anchored to the nucleus through some un-
identified molecule(s) within erythroblasts. Then through a
mechanism whereby dynein binds to g-tubulin and is pulled
toward the plus end of the microtubule, the nucleus anchored
to dynein is pulled along with it [25,27,28]. Within that sce-
nario, EHNA could affect the dynein-containing complex
such that enucleation is inhibited.
Alternatively, it is known that dynein anchored to the
cytoplasmic membrane through the nuclear mitoticapparatus (NuMA) pulls on microtubules bound to g-
tubulin in MTOCs [27]. It is also known that the plus
ends of microtubules are anchored to NuMA and that
NuMA is a key component, along with LGN (Leu–
Gly–Asn repeat-enriched protein) and GiaGDP protein,
of the ternary complexes that form at the plus end of
microtubles [29,30]. However, nuclear localization of
NuMA in mouse erythroblasts has been reported [31].
This suggests human erythroblasts also may not contain
dynein–NuMA complexes anchored to the cytoplasmic
membrane. The precise mechanism of nuclear localiza-
tion dependent on the dynein will be clarified in future
investigations.
We are confident that blockade of enucleation by the
dynein inhibitor EHNA is a specific effect. We
255I. Kobayashi et al./ Experimental Hematology 2016;44:247–256observed an inhibitory effect of 50 mmol/L EHNA
(data not shown) on CFU-E proliferation and of
400 mmol/L on EHNA-blocked enucleation (Fig. 3).
In previous reports, the IC50 of EHNA for dynein
ATPase was 0.23 mmol/L, and this inhibitor is nor-
mally used at concentrations ranging from 0.5 to
2 mmol/L [20,28]. Furthermore, no inhibitory effects
of EHNA (at 0.23 mmol/L) on actomyosin or other AT-
Pases or glycolytic enzymes have been reported [20].
As we presented in this study, no multinucleate cells,
which are produced by actin inhibition with cytocha-
lasin D, appeared on EHNA treatment. The results
indicated that EHNA specifically inhibits dynein
without side effects.
Wang et al. reported that enucleation requires estab-
lishment of cell polarization that is regulated by the
microtubule-dependent local activation of PI3K, and
that its products, phosphatidylinositol 3,4-diphosphate
and phosphatidylinositol 3,4,5-triphosphate, are highly
localized on the cytoplasmic side of the plasma mem-
brane [9]. These inositol phosphates may be useful in
determining the origin of the enucleation site, as PI3K
activation could be identified as the initial signal for
erythroblast enucleation. Wang et al. proposed that
enucleation is regulated by microtubules and PI3K
signaling in a manner mechanistically similar to that
of directed cell locomotion [9]. In their study, a-tubulin
was concentrated at the opposite side of the nucleus and
few microtubule fibers were found in the periphery of
the nucleus. Future experiments are needed to clarify
the relationship between enucleation and cell
locomotion.
In conclusion, our findings indicate dynein is a key
mediator of cell division and nuclear polarization during
terminal differentiation and enucleation of human erythro-
blasts. By contrast, enucleation is independent of most
MTOC-related proteins.Acknowledgments
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Supplementary methods
Reagents and antibodies
Bovine serum albumin (BSA), Iscove’s modified Dulbec-
co’s medium (IMDM), and propidium iodide (PI) were pur-
chased from Sigma-Aldrich (St. Louis, MO). Fetal calf
serum (FCS) was from Flow Laboratories (McLean, VA)
and Hyclone Laboratories (Logan, UT). Penicillin and
streptomycin were from Flow Laboratories. Insulin
(porcine sodium; activity, 28.9 U/mg) was from Wako
Pure Chemical Industries (Osaka, Japan). Interleukin-3
(IL-3) and stem cell factor (SCF) were kind gifts from Kirin
Brewery (Tokyo, Japan). Erythropoietin (EPO) and granu-
locyte colony-stimulating factor (G-CSF) were gifts from
Chugai Pharmaceutical (Tokyo, Japan). Vitamin B12 was
from Eisai (Tokyo, Japan), and folic acid was from Takeda
Pharmaceutical (Osaka, Japan). Triton X-100 was from
Wako Pure Chemical Industries (Osaka, Japan). MACS Mi-
croBeads for Indirect Magnetic Labeling were from Milte-
nyi Biotec (Bergisch-Gladbach, Germany). Alexa Fluor
488- and Alexa Fluor 546-conjugated goat anti-rabbit and
anti-mouse IgGs were from Molecular Probes (Eugene,
OR). Fc-blocking antibody (anti-CD16/32, Clone: 93)
was from eBioscience (San Diego, CA). Normal mouse
and goat sera and rabbit immunoglobulins were from Cell
Signaling Technology (Beverly, MA). Mouse monoclonal
anti-a-tubulin antibody was from Neo Markers (Fremont,
CA). Rabbit polyclonal anti-g-tubulin antibody was from
Abcam (Cambridge, MA). Rabbit monoclonal anti-aurora
A antibody was from Cell Signaling Technology (Beverly,
MA). Rabbit polyclonal anti-aurora B antibody was from
Abcam (Beverly, MA). Rabbit monoclonal anti-
cytoplasmic dynein 1, monoclonal anti-dynein light inter-
mediate chain 1, polyclonal anti-Eg5 and polyclonal
anti-Trim58 were from Abcam (Cambridge, MA). Goat
anti-mouse IgG–HRP was from Santa Cruz Biotechnology
(Santa Cruz, CA). DAPI (40,6-diamidino-2-phenylindole,
dihydrochloride) was from Life Technologies Invitrogen.
Fluorescein isothiocyanate (FITC)-labeled anti-
glycophorin A (GPA-FITC) were purchased from Dako
Japan (Tokyo, Japan), and phosphoerythrin (PE)-labeled
anti-CD71 (CD71-PE) was purchased from BD Biosciences
(Franklin Lakes, NJ). ECL Plus Western Blotting Detection
Reagents were from GE Healthcare UK (Buckinghamshire,
UK). Novex Sharp Protein Standard and NuPAGE Novex
Bis-Tris Mini Gels were from Life Technologies Invitrogen.
Inhibitors
Erythro-9-[3-(2-hydroxynonyl)]adenine (EHNA), a dynein
inhibitor, was from Millipore (Billerica, MA) [20].
Monastrol, an inhibitor of kinesin Eg5, was from Merck
(Whitehouse Station, NJ) [21]. ON-01910, an inhibitor of
polo-like kinase (Plk) 1, and MLN8237, an inhibitor of
aurora A, were from Selleck Chemicals (Houston, TX)
[32–35]. Hesperadin, an inhibitor of aurora B, and
LY294002, an inhibitor of PI3K, were from Cell Signaling
Technology (Beverly, MA) [9,26,36].
Evaluation of enucleation
To evaluate enucleation, cells were spun onto slides using a
Cytospin 3 (Shandon Lipshaw, Pittsburgh, PA) and stained
with May–Gr€unwald–Giemsa. Enucleation was defined as
the expulsion of the nucleus to the outside of the reticulo-
cyte. Reticulocytes touching expelled nuclei or with a
thin connecting strand between the reticulocyte and nucleus
were considered the earliest enucleated cells. The enucle-
ation fraction among the cytospin cells was similar to that
among cells prepared without mechanical force. The
enucleation fraction was calculated using the formula
(erythrocytes/[erythrocytes þ erythroblasts])  100 (%)
with 300 cells, including erythrocytes and erythroblasts,
from each slide [5]. Triplicate cultures were used at each
time point. The yield and viability were determined based
on dye exclusion using 0.2% trypan blue dye [5].
Cell cycle distribution
Cells were harvested, washed with cold 10 mmol/L
Na2HPO4/NaH2PO4, pH 7.4, containing 0.15 mol/L NaCl
(phosphate-buffered saline [PBS]), fixed in 70% ethanol,
and then stored at 20C until analysis. The fixed cells
were centrifuged at 1,200 rpm and washed with cold PBS
twice, after which RNase Awas added to a final concentra-
tion of 0.5 mg/mL, and the cells were incubated for 10 min
at 37C. Thereafter, 25 mg/mL PI was added, and the cells
were incubated for 30 min at room temperature in the dark.
The cells were then analyzed using a FACS Calibur instru-
ment (BD Biosciences, San Jose, CA) equipped with Cell-
Quest 3.3 software as reported previously [5,22,37]. FlowJo
Version 7.2.5 (TOMY Digital Biology, Tokyo, Japan) was
used to determine the cell fractions (%) in the different
cell cycle phases.
Confocal microscopy
Conventional immunocytochemical staining was performed
as described previously [38]. For three-image immunocyto-
chemical staining, the cells were immobilized on poly-L-
lysine-coated slide glass. Fluorescence staining was imaged
using two confocal laser scanning microscopes (LSM510
and LSM710, Carl Zeiss Microscope Systems, Germany)
equipped with 100 objective lenses and 10 camera
lenses (Carl Zeiss Microscope Systems) at zoom 3, as re-
ported elsewhere [5]. Fluorochromes were excited using
an argon laser at 488 nm for Alexa 488. Detector slits
were configured to minimize cross-talk between channels
and processed using ZEN2012 Version 3.2 (Zeiss) and Pho-
toshop (Adobe Systems).
Morphologic and immunochemical analysis of cells
cultured with and without inhibitors
The cells were classified based on the whether the nucleus
was localized at the center of the cells (centered); the cells
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were spherical containing a condensed nucleus located to
one side, close to the plasma membrane (polarized); or
the cells were enucleated (reticulocytes). Other cell types,
such as multinucleate cells and cells with condensed
apoptotic nuclei, were classified as ‘‘other.’’ Images of cells
classified as described are provided in Supplementary
Figure E1 (online only, available at www.exphem.org).
The fractions of each cell type were calculated as described
under Evaluation of Enucleation. Results are presented as
the mean 6 SD of three independent experiments.
Immunochemical distributions of g-tubulin and dynein
were determined using confocal microscopy as described
above. D10 cells were cultured in the presence or absence
of 400 mmol/L EHNA.
Western blot analysis
CD34þ cells were incubated in erythroid medium for the
indicated times. Western blot analysis was carried out as
described previously [5].
Flow cytometry
Cells collected from culture were first washed twice with
IMDM containing 0.3% BSA. They were then incubated
with FITC-conjugated anti-glycophorin A (GPA) and PE-
conjugated CD71, washed twice with staining medium
(10 mmol/L PBS, pH 7.4, 0.5% BSA, and 2 mmol/L
EDTA) and analyzed [37].
Real-time RT-PCR
Total RNAwas extracted from 2  104 cells per sample us-
ing TRizol reagent (Invitrogen). The extracted RNA was
then reverse-transcribed using a SuperScript III First-
Strand Synthesis System for reverse transcription polymer-
ase chain reaction (RT-PCR, Invitrogen) in a 20-mL reaction
volume. The resultant cDNAwas subjected to real-time RT-
PCR using LightCycler 480 SYBR Green I Master (Roche
Applied Science). Relative gene expression levels were
normalized to 28 S. The primers used to assess GATA1
and GLUT1 expression were purchased from Sigma Japan
(Tokyo, Japan). Their sequences are as follows:
GATA1:
50-TCTGGACAACCCAAGTCTCTG-30 (forward)
50-GGCTTGAACCTTCAAAGC-30 (reverse) (GenBank
ID: BC009797)
GLUT1:
50-ATACTCATGACCATCGCGCTAG-30 (forward)
50-AAAGAAGGCCACAAAGCCAAAG-30 (reverse)
(GenBank ID: BC118590.1) [39,40].
Statistical analysis
Statistical analysis was performed using Student’s t test for
parametric data and the Mann–Whitney U test for nonpara-
metric data. Two-tailed p values!0.05 were considered to
indicate significance.
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Supplementary Figure E1. Shown are typical cells classified as centered (nucleus localized at the center of the cells), reticulocyte (enucleated reticulocyte),
polarized (spherical cells containing a condensed nucleus located to one side, close to the plasma membrane), and other (apoptotic or multinucleate). Cells
are stained with May–Gr€unwald–Giemsa reagent.
Supplementary Figure E2. Dynein expression in CFU-Es (D7) incubated
with and without EHNA (400 mmol/L) was analyzed by Western blotting
with an antibody against dynein light intermediated chain 1. a-Tubulin
served as an internal control. Note that dynein was expressed in the pres-
ence of EHNA, indicating the inhibitor did not affect dynein protein
expression in CFU-Es.
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Supplementary Figure E3. To confirm the absence of a nonspecific effect of EHNA on protein expression, the CFU-E populations expressing CD71 and
glycophorin A (GPA) in the presence and absence of EHNA (400 mmol/L) were analyzed using flow cytometry. The results indicate that EHNA blocked
proliferation of CFU-Es by inhibiting dynein.
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Supplementary Figure E4. Real-time RT-PCR of GATA1 and GLUT1 in
CFU-Es treated with () or without (B) EHNA. Three independent exper-
iments were performed, and the data are presented as the average and SE.
There were no significant differences between CFU-Es incubated for
24 hours with or without EHNA.
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Supplementary Figure E5. Human D7 CFU-Es generated from purified CD34þ cells were cultured for the indicated periods in the presence of EPO with or
without inhibitors of Eg5 (monastrol, A–C) or PI3K (LY294002, D–F). (A, D) Effects of the indicated concentrations of inhibitors or vehicle on CFU-E
proliferation. Results are presented as the means 6 SD of three independent experiments. (B, E) Cell cycle analysis of D8 cells after culture for 24 hours
with (red areas) or without (solid lines). A representative result from three independent experiments is presented as the mean 6 SD. (C, F) May–Gr€unwald–
Giemsa staining of D8–D9 cells after culture for 24 or 48 hours with or without 100 mmol/L monastrol (C) and 100 mmol/L LY294002 (F). A representative
result from three independent experiments is shown. Bar 5 10 mm. Note that after 7 days of culture (D7) in the presence of monastrol, however, cells of
various sizes were observed, some with condensed nuclei (deeply stained).
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Supplementary Figure E7. To confirm the absence of a nonspecific effect of EHNA on protein expression, the D10 cell populations expressing CD71 and
glycophorin A (GPA) in the presence and absence of EHNA (400 mmol/L) were analyzed using flow cytometry. After incubation for 48 hours in the presence
of EHNA, the population of double-positive (CD71þ and GPAþ) D10 cells was unchanged. By contrast, among those incubated in the absence of EHNA, the
population of double-positive cells was increased. These results indicate that EHNA blocked enucleation of the D10 cells by inhibiting dynein.
Supplementary Figure E6. Dynein expression in D10 cells incubated
with and without EHNA (400 mmol/L) was analyzed by Western blotting
with an antibody against dynein light intermediated chain 1. a-Tubulin
served as an internal control. Note that dynein was expressed in the pres-
ence of EHNA, indicating the inhibitor did not affect dynein protein
expression in D10 cells.
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Supplementary Figure E8. Real-time RT-PCR of GATA1 and GLUT1 in
D10 cells treated with () or without (B) EHNA is shown. Three indepen-
dent experiments were performed, and the data are presented as the
average and SE. After incubation of the cells with or without 400 mM
EHNA for 24 hours, there were no significant differences in mRNA levels.
After 72 hours, however, levels of both GATA1 and GLUT1 mRNA were
reduced in D10 cells exposed to EHNA.
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Supplementary Figure E10. Graphic presentation of the nuclear positioning in D10 cells incubated with inhibitors of the indicated proteins. Data are sum-
marized in Table 1.
Supplementary Figure E9. D10 cells were cultured for 3 days in the presence of EPO with or without inhibitors Eg5 (monastrol, A–C) and PI3K
(LY294002, D–F). (A, D) Effects of the indicated concentrations of inhibitors or vehicle on enucleation of D11–D13 erythroblasts. Results are presented
as the means 6 SD of three independent experiments. (B, E) Cell cycle analysis of D11 cells after culture for 24 hours with (red lines) or without (black
lines) 100 mmol/L monastrol (B) and 100 mmol/L LY294002 (E). A representative result from three independent experiments is presented as the mean 6 SD.
(C, F) May–Gr€unwald–Giemsa staining of D11–D13 cells after culture for 24, 48, or 72 hours with or without 100 mmol/L monastrol (C) and 100 mmol/L
LY294002 (F). A representative result from three independent experiments is shown. Bar 5 10 mm.
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Supplementary Figure E12. Confocal micrographs of enucleating erythroblasts (D11) stained with DAPI (blue) and antibodies against dynein (green) and
a-tubulin (red). The differential interference contrast microscopic image (DIC) is labeled. Overlap of the dynein and a-tubulin staining is shown in yellow in
the merged image. Bar 5 10 mm.
Supplementary Figure E11. Three-dimensional confocal micrographs of a D11 cell stained with anti-a-tubulin (red), anti-g-tubulin (green, indicated by
arrow). The differential interference contrast microscopic image (DIC) is labeled. Overlap of the a-tubulin and g-tubulin staining is shown in yellow in the
merged image (indicating by arrowhead in DIC image). Bar 5 10 mm.
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Supplementary Figure E13. Confocal micrographs of CFU-Es (D7 or D8) and enucleating erythroblasts (D11) stained with DAPI (blue) and antibodies
against a-tubulin (red) plus antibodies against Eg5 (A), Plk1 (B), aurora A (C), or aurora B (D) (green, indicated by arrowheads). Overlap of the respective
distributions is shown in yellow in the merged images. Bar 5 10 mm.
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Supplementary Figure E14. Expression of Tim58 and dynein during
erythropoiesis. Shown are Western blots of human CFU-Es (D7), erythro-
blasts (D9 and D11) and enucleated reticulocytes (D13). CFU-Es gener-
ated from purified CD34þ cells were cultured for the indicated periods,
after which cells were harvested, and protein from 1  105 cells was
applied to each lane. Expression of a-tubulin, Teim58, dynein intermediate
chain 2, and dynein light intermediate chain 1 was analyzed using specific
antibodies against these antigens.
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